Dr. Robert M. Wenham, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 90
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
FL license ME92703
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- H Lee Moffitt Cancer Ctr and Res Inst Life Time Cancer Scrn Ctr Inc (1,178 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 232
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 37 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 17 | 15 |
| Established patient office or other outpatient visit, 10-19 minutes | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 6 companies reported 15 payments worth $11,565 in total to this clinician.
| Corcept Therapeutics | $6,204 |
|---|---|
| On Target Laboratories, Inc | $3,795 |
| Genmab U.S., Inc. | $1,050 |
| Eisai Inc. | $289 |
| AbbVie Inc. | $120 |
| Merck Sharp & Dohme LLC | $107 |
| Compensation for services other than consulting (speaking, faculty) | $5,400 |
|---|---|
| Consulting Fee | $4,845 |
| Travel and Lodging | $672 |
| Food and Beverage | $648 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Corcept Therapeutics Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionADVISORY FEE | $5,400 |
| On Target Laboratories, Inc Aug 7, 2025 | Consulting Fee Cytalux · Oncology | $2,795 |
| On Target Laboratories, Inc Oct 9, 2025 | Consulting Fee Cytalux · Oncology | $1,000 |
| Genmab U.S., Inc. Aug 1, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $525 |
| Genmab U.S., Inc. Sep 5, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $525 |
| Corcept Therapeutics Nov 7, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind Company’s descriptionAIRFARE AND TRAIN | $422 |
| Corcept Therapeutics Dec 5, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind Company’s descriptionLODGING | $214 |
| Corcept Therapeutics Dec 23, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind Company’s descriptionTRAVEL OTHERS | $36.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $223,295 in research payments for these studies, mostly to the institutions running them.
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT04590326 - Study name not reported
Iovance Biotherapeutics, Inc. - NCT03108495
Iovance Biotherapeutics, Inc. - NIR-OGT-201
Springworks Therapeutics, Inc. - A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT…
Merck Sharp & Dohme LLC - ";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with a germline BRCA mutation and Stage III-IV Ovarian Cancer who are in Complete or Parti…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.